Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVBP 
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.56
1 Year Target Price $39.56
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.3% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 799.61M USD | Price to earnings Ratio - | 1Y Target Price 39.56 |
Price to earnings Ratio - | 1Y Target Price 39.56 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 15.47 - 36.37 | Updated Date 09/15/2025 |
52 Weeks Range 15.47 - 36.37 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.41% | Return on Equity (TTM) -50.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 564024886 | Price to Sales(TTM) - |
Enterprise Value 564024886 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 40568900 | Shares Floating 21604180 |
Shares Outstanding 40568900 | Shares Floating 21604180 | ||
Percent Insiders 8.24 | Percent Institutions 83.06 |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. Founded in 2021, it is focused on identifying, developing and commercializing innovative therapies for the treatment of cancer. It went public in January 2024.
Core Business Areas
- Oncology Drug Development: Focuses on acquiring and developing innovative oncology therapies, primarily targeted at the Chinese market.
Leadership and Structure
Bing Yao, Ph.D., serves as Chairman, CEO and President. The company operates with a standard corporate structure, including a board of directors and various functional departments such as R&D, clinical development, and business development.
Top Products and Market Share
Key Offerings
- Furmonertinib: A novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that ArriVent is developing for non-small cell lung cancer (NSCLC). Market share data is currently unavailable as it is still in development. Competitors include AstraZeneca (Tagrisso), Roche (Tarceva), and other EGFR-TKI developers.
Market Dynamics
Industry Overview
The oncology drug market is rapidly growing, driven by aging populations and advances in cancer research. Targeted therapies and immunotherapies are key growth areas.
Positioning
ArriVent aims to establish itself as a leader in developing and commercializing innovative cancer therapies, particularly in the Chinese market.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. ArriVent aims to capture a significant share of the market by focusing on innovative therapies and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Promising lead product candidate (Furmonertinib)
- Focus on the large and growing Chinese oncology market
- Strategic partnerships for development and commercialization
Weaknesses
- Reliance on a single lead product candidate
- Limited commercial infrastructure
- High R&D expenses
- Dependence on strategic partnerships
Opportunities
- Expansion of product pipeline through acquisitions or in-licensing
- Successful clinical trials and regulatory approvals for Furmonertinib
- Growth in the Chinese oncology market
- Potential for strategic collaborations with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in the Chinese healthcare market
Competitors and Market Share
Key Competitors
- AZN
- ROG.SW
Competitive Landscape
ArriVent faces competition from established pharmaceutical companies with larger R&D budgets and commercial infrastructure. The company's competitive advantage lies in its focus on innovative therapies and the Chinese market.
Growth Trajectory and Initiatives
Historical Growth: Not Applicable.
Future Projections: Future growth is dependent on the successful development and commercialization of Furmonertinib and other pipeline products. Analyst estimates will become available as more data emerges.
Recent Initiatives: Focus on advancing Furmonertinib through clinical trials and building a strong commercial infrastructure in China.
Summary
ArriVent BioPharma is an early-stage biopharmaceutical company with promising potential, particularly in the Chinese oncology market. The company's success hinges on the clinical development and regulatory approval of Furmonertinib. They face challenges related to competition and financial constraints, which the management needs to carefully mitigate. While new to the market, its strategic partnerships and leadership team are key components to watch for potential upside.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.